Brind.

EXEL announced that its drug candidate, zanzalintinib, inhibits MET activity and also shows activity against MER.

4 reports, 3 independent Updated Sat 00:00

No new developments lately

Reports: 4
Developments: 2
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

EXEL announced that its drug candidate, zanzalintinib, inhibits MET activity and also shows activity against MER.

Who's involved

What this event is mainly about

EXEL Met Mer

How it developed

Newest first. Tap a step to see who reported it.

Jul 1FDA reviews application for zanzalintinib combination therapy.1 source
- yahoo.com
Aug 13zanzalintinib shown to inhibit MET and MER activities.1 source
- Zacks

Keep exploring

The entities involved

EXEL
Czech company

Nothing else this week.
Met
river in Komi, Russia, tributary of Lepyu, upper tributary of Sysola
- George Saunders' novel is the subject of multiple concurrent cultural events, including a university initiative, a production at the Met, and a TV appearance with Stephen Colbert.Sun 17:41
Mer
Norwegian operator of charging stations

Nothing else this week.

Coverage

Newest first; wire copies grouped

Sat 00:00fool.com
Jul 1yahoo.com
Aug 13ZacksWill Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? Exelixis (EXEL) is developing zanzalintinib — a next-generation oral investigational tyrosine kinase inhibitor (TKI) — which inhib
Jun 24Unknown outlet